Leerink Partnrs Issues Optimistic Outlook for FOLD Earnings

Amicus Therapeutics, Inc. (NASDAQ:FOLD) – Analysts at Leerink Partnrs boosted their Q4 2024 earnings per share estimates for Amicus Therapeutics in a research note issued to investors on Monday, January 20th. Leerink Partnrs analyst J. Schwartz now forecasts that the biopharmaceutical company will post earnings per share of ($0.03) for the quarter, up from their prior estimate of ($0.04). The consensus estimate for Amicus Therapeutics’ current full-year earnings is ($0.04) per share. Leerink Partnrs also issued estimates for Amicus Therapeutics’ Q1 2025 earnings at ($0.05) EPS.

Several other research firms also recently issued reports on FOLD. Needham & Company LLC reissued a “hold” rating on shares of Amicus Therapeutics in a research report on Monday, January 13th. Morgan Stanley reissued an “equal weight” rating and issued a $12.00 price objective (down from $17.00) on shares of Amicus Therapeutics in a report on Friday, December 13th. Guggenheim lifted their target price on Amicus Therapeutics from $13.00 to $15.00 and gave the stock a “buy” rating in a report on Thursday, November 7th. Bank of America increased their price target on shares of Amicus Therapeutics from $13.00 to $15.00 and gave the stock a “buy” rating in a report on Thursday, October 17th. Finally, StockNews.com cut shares of Amicus Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, December 18th. Three research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $16.88.

Amicus Therapeutics Stock Up 1.1 %

NASDAQ:FOLD opened at $9.51 on Wednesday. The company has a current ratio of 3.15, a quick ratio of 2.42 and a debt-to-equity ratio of 2.18. Amicus Therapeutics has a twelve month low of $8.78 and a twelve month high of $14.03. The company has a market cap of $2.84 billion, a PE ratio of -27.97, a P/E/G ratio of 1.43 and a beta of 0.62. The company’s 50 day moving average is $9.66 and its two-hundred day moving average is $10.52.

Insider Buying and Selling at Amicus Therapeutics

In other news, CEO Bradley L. Campbell sold 7,901 shares of the business’s stock in a transaction that occurred on Wednesday, November 6th. The stock was sold at an average price of $12.50, for a total value of $98,762.50. Following the completion of the sale, the chief executive officer now directly owns 886,654 shares in the company, valued at $11,083,175. The trade was a 0.88 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Over the last quarter, insiders sold 22,901 shares of company stock valued at $259,863. Corporate insiders own 2.20% of the company’s stock.

Institutional Investors Weigh In On Amicus Therapeutics

A number of institutional investors have recently added to or reduced their stakes in the stock. Wellington Management Group LLP lifted its holdings in Amicus Therapeutics by 13.5% during the third quarter. Wellington Management Group LLP now owns 23,964,044 shares of the biopharmaceutical company’s stock valued at $255,936,000 after purchasing an additional 2,856,101 shares in the last quarter. Neo Ivy Capital Management purchased a new position in Amicus Therapeutics in the 3rd quarter valued at about $702,000. Connor Clark & Lunn Investment Management Ltd. boosted its holdings in Amicus Therapeutics by 51.5% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 222,934 shares of the biopharmaceutical company’s stock worth $2,381,000 after buying an additional 75,807 shares during the last quarter. Charles Schwab Investment Management Inc. increased its stake in Amicus Therapeutics by 10.0% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 2,667,271 shares of the biopharmaceutical company’s stock worth $28,486,000 after buying an additional 242,672 shares in the last quarter. Finally, Mutual of America Capital Management LLC raised its holdings in shares of Amicus Therapeutics by 24.2% during the second quarter. Mutual of America Capital Management LLC now owns 250,293 shares of the biopharmaceutical company’s stock valued at $2,483,000 after acquiring an additional 48,802 shares during the last quarter.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.